OFFICER DOWN: How TJ Webb Got Shot 6 Times & Lived to Tell The Tale | Mike Drop Ep. 208November 1, 2026
Robert W. Brown on November 1, 2026 6:50 am Exploration results look promising, but permitting will be the key risk. Reply
Michael Thompson on November 1, 2026 6:51 am Nice to see insider buying—usually a good signal in this space. Reply
Patricia Rodriguez on November 1, 2026 6:51 am Interesting update on Rick Doblin – MDMA Psychedelic Assisted Therapy | SRS #97. Curious how the grades will trend next quarter. Reply
Emma Moore on November 1, 2026 6:53 am Nice to see insider buying—usually a good signal in this space. Reply
Linda Miller on November 1, 2026 6:53 am If AISC keeps dropping, this becomes investable for me. Reply
Amelia Martin on November 1, 2026 6:54 am The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Ava Thomas on November 1, 2026 6:54 am Interesting update on Rick Doblin – MDMA Psychedelic Assisted Therapy | SRS #97. Curious how the grades will trend next quarter. Reply
Noah Martinez on November 1, 2026 6:55 am The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Lucas Garcia on November 1, 2026 6:56 am I like the balance sheet here—less leverage than peers. Reply
Ava Thompson on November 1, 2026 6:56 am If AISC keeps dropping, this becomes investable for me. Reply
John X. Lopez on November 1, 2026 6:57 am Production mix shifting toward Videos might help margins if metals stay firm. Reply
Emma Moore on November 1, 2026 6:57 am Interesting update on Rick Doblin – MDMA Psychedelic Assisted Therapy | SRS #97. Curious how the grades will trend next quarter. Reply
Amelia Garcia on November 1, 2026 6:58 am Silver leverage is strong here; beta cuts both ways though. Reply
Jennifer Lee on November 1, 2026 6:58 am Exploration results look promising, but permitting will be the key risk. Reply
Olivia Jones on November 1, 2026 7:00 am I like the balance sheet here—less leverage than peers. Reply
Isabella C. Martinez on November 1, 2026 7:53 am Good point. Watching costs and grades closely. Reply
Jennifer G. Taylor on November 1, 2026 7:00 am Uranium names keep pushing higher—supply still tight into 2026. Reply
Michael Moore on November 1, 2026 7:01 am Silver leverage is strong here; beta cuts both ways though. Reply
Liam Jackson on November 1, 2026 7:01 am The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Isabella Rodriguez on November 1, 2026 7:01 am The cost guidance is better than expected. If they deliver, the stock could rerate. Reply
Isabella Martin on November 1, 2026 7:02 am Uranium names keep pushing higher—supply still tight into 2026. Reply
Amelia Garcia on November 1, 2026 7:02 am Interesting update on Rick Doblin – MDMA Psychedelic Assisted Therapy | SRS #97. Curious how the grades will trend next quarter. Reply
Noah H. Brown on November 1, 2026 7:03 am Exploration results look promising, but permitting will be the key risk. Reply
47 Comments
Exploration results look promising, but permitting will be the key risk.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Interesting update on Rick Doblin – MDMA Psychedelic Assisted Therapy | SRS #97. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
If AISC keeps dropping, this becomes investable for me.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Interesting update on Rick Doblin – MDMA Psychedelic Assisted Therapy | SRS #97. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
If AISC keeps dropping, this becomes investable for me.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Production mix shifting toward Videos might help margins if metals stay firm.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Interesting update on Rick Doblin – MDMA Psychedelic Assisted Therapy | SRS #97. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
If AISC keeps dropping, this becomes investable for me.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
Uranium names keep pushing higher—supply still tight into 2026.
Silver leverage is strong here; beta cuts both ways though.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Interesting update on Rick Doblin – MDMA Psychedelic Assisted Therapy | SRS #97. Curious how the grades will trend next quarter.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.